Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/20/2017 07/21/2017 07/24/2017 07/25/2017 07/26/2017 Date
245.3(c) 244(c) 242.6(c) 242.1(c) 242.2 Last
1 664 145 1 534 243 1 274 706 1 127 865 391 379 Volume
+0.49% -0.53% -0.57% -0.21% +0.04% Change
More quotes
Financials ( CHF)
Sales 2017 53 066 M
EBIT 2017 18 191 M
Net income 2017 11 382 M
Debt 2017 9 070 M
Yield 2017 3,54%
Sales 2018 55 422 M
EBIT 2018 19 270 M
Net income 2018 12 262 M
Debt 2018 4 836 M
Yield 2018 3,73%
P/E ratio 2017 17,72
P/E ratio 2018 16,49
EV / Sales2017 4,13x
EV / Sales2018 3,88x
Capitalization 210 335 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
07/25 ROCHE HOLDING LTD. : Levi & Korsinsky, LLP Notifies Shareholders of Roche Holdin..
07/25 REMINDER : Invitation to Roche Analyst Event on Diagnostics Division at AACC 201..
07/24 ROCHE HOLDING LTD. : TWO WEEK DEADLINE: Lundin Law PC Announces Securities Class..
07/24 ROCHE HOLDING LTD. : IMMINENT ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faru..
07/24 ROCHE HOLDING LTD. : The Klein Law Firm Reminds Investors of a Class Action File..
07/24 ROCHE : CRICKET-U19s-SCOREBOARD Zimbabwe U-19s vs Zimbabwe U-19s - 1st YODI
07/24 ROCHE : Foreign Drugs into China MI Drug List on Cutting Prices
07/22 ROCHE : exits epigenetic drug deal
07/22 ORYZON GENOMICS : Roche Abandons Spanish Cancer Epigenetics Drug
07/22 ROCHE : s new breast cancer drug that could cut treatment time denied patent
More news
Sector news : Pharmaceuticals - NEC
07/25DJGlaxoSmithKline Names Former Wal-Mart Executive as Chief Digital and Technolo..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/25DJABBVIE : Jury Backs AbbVie Payment -- WSJ
07/25DJSamsung Enters U.S. Drug Market -- WSJ
07/24DJABBVIE : Ordered to Pay $150 Million in AndroGel Lawsuit
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
2016An opportunity over the medium term?
2016A medium term support level to take advantage of
More Strategies
Latest Tweets
03:50aRoche gains CE label expansion for companion diagnostic to identify ALK-posit.. 
07/25$RHHBY: Roche Hldg has obtained a CE mark for the VENTANA anti-ALK (D5F3) Rab.. 
07/25Global Liver Disease Treatment Market 2017-2021: Key Vendors are F. Hoffmann-.. 
07/25Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2.. 
07/25$SENS: Senseonics announces collaboration w/ TypeZero and Roche (RHHBY) to de.. 
More tweets
Qtime:143
News from SeekingAlpha
07/25 Don't Lose The Faith In Shire
07/24 Seattle Genetics teams up with Roche's Genentech to evaluate ADC/Tecentriq co..
07/23 Tracking Ken Fisher'S Fisher Asset Management Portfolio - Q2 2017 Update
07/23 WEEK IN REVIEW : C-Bridge Raises $400 Million For Second China Healthcare Fund
07/21 European advisory group backs approval of 11 new meds
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 282  CHF
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.4.30%220 599
JOHNSON & JOHNSON14.47%358 307
NOVARTIS7.35%220 169
PFIZER1.91%198 425
MERCK AND COMPANY5.93%171 139
SANOFI7.50%120 362